Fortrea Holdings Inc. Form 8-K Summary
Reporting date: May 3, 2024. The filing reports financing actions entered into on May 3 and May 6, 2024; it was signed on May 9, 2024.
Business Context and Reporting Period
Fortrea Holdings Inc. is a clinical research services company. This Form 8-K does not report quarterly operating results; it discloses amendments to the company’s senior credit agreement, a new receivables securitization program, and termination of an existing accounts receivable purchase program.
Key Financial and Liquidity Matters
- Fortrea entered into a three-year, $300 million receivables securitization program with PNC Bank, National Association, scheduled to terminate on May 6, 2027 unless terminated earlier.
- Under the program, Fortrea’s special purpose entity may sell eligible receivables to purchasers in exchange for funding. The applicable yield is generally based on the one-month term secured overnight financing rate, plus customary fees.
- The filing does not provide a clear amount drawn or outstanding under the new facility at closing.
- The company terminated its prior accounts receivable purchase program, which had provided capacity of approximately $80 million. No customer receivables were factored under that program at termination.
- Fortrea paid a fee to consenting lenders in connection with the credit agreement amendment. The filing does not provide the fee amount.
Material Changes Versus the Prior Comparable Period
- The new $300 million receivables facility replaces the prior approximately $80 million ARPP, increasing stated receivables-financing capacity by approximately $220 million, although actual availability and usage depend on eligibility and other conditions.
- The amendment temporarily relaxed financial covenants under the existing senior credit facility.
| Financial covenant | Prior level | Temporary amended level |
|---|---|---|
| Maximum Total Leverage Ratio | 5.30:1.00 | 6.00:1.00 for quarters ending June 30 and September 30, 2024; 5.75:1.00 for December 31, 2024 and March 31, 2025; 5.50:1.00 for June 30, 2025; then 5.30:1.00 |
| Minimum Interest Coverage Ratio | 2.00:1.00 | 1.70:1.00 for quarters ending June 30 and September 30, 2024; 1.80:1.00 for December 31, 2024 and March 31, 2025; 1.90:1.00 for June 30, 2025; then 2.00:1.00 |
Guidance, Outlook, Risks, and Unusual Items
- During the covenant adjustment period, the company agreed to additional limitations on investments and restricted payments.
- Net cash proceeds from the previously announced divestiture of Fortrea Patient Access and Endpoint businesses must be applied to repay senior indebtedness.
- The receivables agreements include funding conditions, representations and warranties, covenants, servicing obligations, indemnification provisions, and events of default that may accelerate amounts owed.
- The filing provides no operating or earnings guidance.
- Management cautions that forward-looking statements and expected financial outcomes are subject to risks described in the company’s SEC filings, including its Form 10-K risk factors.
Investor Verification Checklist
- Verify the final executed receivables purchase and sale agreements when filed with the company’s Form 10-Q for the quarter ending June 30, 2024.
- Confirm the amount, classification, and accounting treatment of any receivables sold or funded under the new facility.
- Review the company’s debt balances, covenant compliance, and liquidity following the amendment.
- Verify the timing and net proceeds of the Patient Access and Endpoint divestiture and the related debt repayment.
- Assess the restrictions on investments and restricted payments and the consequences of any event of default.